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Background: Observational studies have associated adiposity with an increased risk of colorectal cancer (CRC). However, such
studies do not establish a causal relationship. To minimise bias from confounding we performed a Mendelian randomisation (MR)
analysis to examine the relationship between adiposity and CRC.
Methods: We used SNPs associated with adult body mass index (BMI), waist-hip ratio (WHR), childhood obesity and birth weight
as instrumental variables in a MR analysis of 9254 CRC cases and 18 386 controls.
Results: In the MR analysis, the odds ratios (ORs) of CRC risk per unit increase in BMI, WHR and childhood obesity were 1.23 (95%
CI: 1.02–1.49, P¼ 0.033), 1.59 (95% CI: 1.08–2.34, P¼ 0.019) and 1.07 (95% CI: 1.03–1.13, P¼ 0.018), respectively. There was no
evidence for association between birth weight and CRC (OR¼ 1.22, 95% CI: 0.89–1.67, P¼ 0.22). Combining these data with a
concurrent MR-based analysis for BMI and WHR with CRC risk (totalling to 18 190 cases, 27 617 controls) provided increased
support, ORs for BMI and WHR were 1.26 (95% CI: 1.10–1.44, P¼ 7.7 10 4) and 1.40 (95% CI: 1.14–1.72, P¼ 1.2 10 3),
respectively.
Conclusions: These data provide further evidence for a strong causal relationship between adiposity and the risk of developing
CRC highlighting the urgent need for prevention and treatment of adiposity.
Colorectal cancer (CRC) is a major public health problem in
economically developed countries (Forman et al, 2014). Migration
and epidemiological studies have established that diet and other
lifestyle factors have a major role in the aetiology of CRC (Haggar
and Boushey, 2009). Among the lifestyle factors that have an
impact on CRC risk, high body mass index (BMI) has generally
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been reported to be associated with an increased risk in
observational studies (Bianchini et al, 2002; Bardou et al, 2013),
with some evidence for a stronger influence being shown for men
(Pan et al, 2004; Moghaddam et al, 2007). There is also evidence
for an inverse relationship between adiposity at a young age and
cancer development (Carpenter et al, 2003; Yang et al, 2014).
The association between BMI and CRC in these observational
studies does not, however, necessarily establish a causal relation-
ship. Specifically, these studies cannot entirely exclude the
possibility of the observed association being the consequence of
confounding factors, such as socio-economic status, alcohol and
other lifestyle factors (Moghaddam et al, 2007), whereas some
studies have failed to exclude the possibility of reverse causation
(Smith and Ebrahim, 2003).
An alternative to a traditional observational epidemiology study is
the Mendelian randomisation (MR) approach. The strategy of MR
uses genetic markers known to be associated with a potential risk
factor in the assessment of its effect on another trait or disease
(Lawlor et al, 2008). These markers, or instrumental variables (IV),
rely on a number of assumptions, namely that the IVs are solely
associated with the trait or disease, and the IVs are independent of
confounders. This methodology permits the nature of the relation
between the risk factor and the trait or disease to be assessed without
the limitations present within observational studies, such as
confounding factors, and importantly establish whether an association
is causal. A further attribute of MR is the avoidance of the influence of
factors whose effect may be time sensitive, for example weight loss
being a consequence of CRC. Thus, an IV has the potential to more
accurately assess lifetime exposure when compared with measure-
ments of potential risk factors recorded in an observational study.
In the present study we examined, using MR, the impact of four
metrics of adiposity on the risk of developing CRC. The adiposity
traits we considered were adult BMI, adult waist-hip ratio (WHR),
childhood obesity and birth weight.
MATERIALS AND METHODS
CRC GWAS data sets. Our MR analysis was based on data from
seven previously reported genome-wide association studies
(GWAS) of CRC (Orlando et al, 2016). Briefly, these GWAS were
all based on individuals with European ancestry and comprise:
CCFR1 (1290 cases, 1055 controls), CCFR2 (796 cases, 2236
controls), COIN (2244 cases, 2162 controls), FINLAND (1172
cases, 8266 controls), UK1 (940 cases, 965 controls), Scotland1
(1012 cases, 1012 controls) and VQ58 (1800 cases, 2690 controls).
Details of the genotyping, quality control and imputation of
untyped single-nucleotide polymorphisms (SNPs) genotypes
have been previously published. Summary statistics from the
GWAS were used to calculate the ratio estimates for the adiposity-
related SNPs.
Instrumental variables. For each of four adiposity traits (adult
BMI, adult WHR, childhood obesity and birth weight), we used
data from recent GWAS of individuals of European-decent for
each trait. Specifically for adult BMI, we used data from the
Genetic Investigation of Anthropometric Traits (GIANT) con-
sortium, which was based on an analysis of up to 339 224
individuals (Locke et al, 2015). For the WHR, data were obtained
from a meta-analysis comprising 61 studies, made up of up to
190 803 individuals (Heid et al, 2010). For childhood obesity, data
was obtained from 2480 children with extreme obesity and 7370
controls (Wheeler et al, 2013). Birth weight data was obtained from
up to 69 308 individuals from 43 studies (Horikoshi et al, 2013).
We used SNPs that were declared genome-wide significant (i.e.,
Pp5.0 10 8) in these GWAS as IVs. From the 97 adult BMI-
associated SNPs (kgm 2) as identified by Locke et al (2015), we
confined the analysis to 76 SNPs that were found in European
populations, and were separated by at least 500 kb. In addition, we
used 14 SNPs for WHR as reported by Heid et al (2010); nine SNPs
reported by Wheeler et al (2013), which were associated with
childhood obesity (43 s.d. from the mean of the BMI
distribution); and the seven SNPs reported by Horikoshi et al
(2013), which were associated with birth weight (kg)
(Supplementary Table 1). None of these studies reported non-
additive effects of the SNPs on the adiposity trait, hence per allele
effects were considered additive. For each of the four adiposity
traits we extracted the effect estimates and associated P-values of
each SNP from the seven CRC GWAS.
Statistical analysis. We performed MR analysis to assess the
association between each adiposity trait and CRC using summary
statistics from the CRC GWAS, and the published effect size of the
adiposity-related trait on CRC. As per Burgess et al (2015) the
combined ratio estimate ðb^Þ of all SNPs associated with a
particular adiposity trait on CRC risk was calculated under a
fixed-effects model:
b^ ¼
P
k XkYks
2
YkP
k X
2
ks
2
Yk
:
Xk corresponds to the association between SNP k with the
adiposity trait and Yk is the association between SNP k and CRC
risk with standard error sYk . The standard error of the combined
ratio estimate is approximately given by
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We used MR-Egger and inverse weighted variance regression to
examine for violation (e.g., from pleiotopy) of the standard IV
assumptions in our analysis (Bowden et al, 2015). All analyses were
performed using R software (R Development Core Team, Vienna,
Austria) and we considered a P-value of o0.05 as significant.
Meta-analysis with published studies. An overlapping concurrent
study has recently been published which has also reported an MR
analysis to estimate the causal association between adiposity and
CRC risk (Thrift et al, 2015). The study was based on the analysis
of 10 226 CRC cases and 10 286 controls from 11 GWAS, including
the CCFR1 study, reporting on the impact of adult BMI and WHR
on CRC. The genetic risk score for these two adiposity traits in this
study and in our analysis was based on the same set of SNPs.
Hence, to enhance our power to establish a relationship between
genetically defined adiposity and CRC risk, we performed a meta-
analysis of our study and this published study pooling summary
estimates of effect size under a fixed-effects model, avoiding
duplication of the CCFR1 study.
RESULTS
In six of the seven CRC GWAS there was a positive relationship
between BMI-increasing alleles and CRC risk (Figure 1). From the
pooled analysis we identified an odds ratio (OR) of 1.23 in risk of
CRC per kgm 2 increase of BMI (95% confidence interval (CI):
1.02–1.49, P¼ 0.033, test for heterogeneity between studies
I2¼ 0%, Phet¼ 0.70).
Although the relationship between WHR and childhood obesity
with CRC was less consistent between studies than for BMI in the
pooled analysis, we also identified a correlation between both
adiposity traits and CRC risk (Figure 1). For each unit increase in
WHR we observed an OR of 1.59 in CRC risk (95% CI: 1.08–2.34,
P¼ 0.019 test for heterogeneity across studies I2¼ 45%,
Phet¼ 0.09). For childhood obesity the OR for CRC was 1.07
Mendelian randomisation of adiposity and CRC BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2016.188 267
(95% CI: 1.01–1.13, P¼ 0.018, test for heterogeneity between
studies I2¼ 0%, Phet¼ 0.61). In contrast to the relationship
between BMI, WHR, and childhood obesity and CRC we observed
no association with birth weight and risk (P¼ 0.22, Figure 1).
Using both MR-Egger and IVW regression tests we did not
detect violation of the standard IV assumptions in our MR analysis
of BMI, WHR, childhood obesity or birth weight for CRC risk
(Supplementary Figure 1, Supplementary Table 2).
The strongest reported SNP associations for BMI are provided
by rs1558902 (FTO) and rs13021737 (TMEM18), which have a
well-established impact on obesity (Frayling et al, 2007; Rohde
et al, 2014). To examine if our findings of a correlation between
BMI and CRC risk were primarily driven by these variants we
performed a sensitivity analysis excluding these SNPs. The MR
results remain statistically significant, albeit slightly less profound
(OR¼ 1.24, 95% CI: 1.01–1.51, P¼ 0.035). The association
between each of the adiposity-related SNP and CRC risk is shown
in Supplementary Figure 1.
Given there is correlation between measures of adiposity
(Serdula et al, 1993) we examined the specificity of each trait on
CRC risk by repeating our analysis omitting SNPs if there were
overlapping loci. With the exception of adult BMI and childhood
obesity which share four associated loci FTO (rs1558902,
rs1421085), MC4R (rs6567160, rs476828), TMEM18 (rs13021737,
rs12463617) and NEGR1 (rs3101336) all of the adiposity-related
SNPs are distinct. Omitting these overlapping SNPs from our MR
analysis still provided evidence for a correlation between adult BMI
and childhood obesity with CRC risk, albeit less significant than
before (OR¼ 1.23, 95% CI: 1.00–1.51, P¼ 0.049 and OR¼ 1.10,
95% CI: 1.02–1.20, P¼ 0.019, respectively).
To explore if there were gender-specific associations for CRC for
each of the four adiposity traits, we performed a stratified analysis
of our data set. Although an increasing number of risk alleles for
each trait was associated with an increased CRC in both men and
women, only the relationship between adult WHR and CRC in
men remained statistically significant (Supplementary Table 3;
OR¼ 2.13, 95% CI: 1.18–3.87, P¼ 0.013).
In the meta-analysis combining these results with the data from
Thrift et al (2015), adult BMI was associated with an OR of 1.26 for
CRC risk (95% CI: 1.10–1.44, P¼ 7.7 10 4) and adult WHR an
OR of 1.40 for CRC risk (95% CI: 1.14–1.72, P¼ 1.2 10 3;
Table 1). Although the association between genetically influenced
adult BMI was only significant in women (ORs in females and
males were 1.43, 95% CI: 1.17–1.74, P¼ 4.3 10 4 and 1.12, 95%
CI: 0.92–1.38, P¼ 0.26, respectively) and the WHR association was
only significant for men (ORs in males and females were 1.63, 95%
CI: 1.20–2.22, P¼ 2.0 10 3 and 1.22, 95% CI: 0.91–1.63,
P¼ 0.18, respectively) these differences were not statistically
different (P-values for difference were 0.09 and 0.18, respectively).
DISCUSSION
In this study we have shown correlations between IVs for adult
BMI, WHR and childhood obesity, and CRC risk. Even adjusting
for multiple testing the correlations between IVs for adult BMI and
WHR remained significant. The absence of data on childhood
obesity in the study reported by Thrift et al (2015), precluded
meta-analysis of this metric of adiposity. We did not identify a
relationship between the IVs for birth weight and CRC. Although
this is less likely to be a determinant of CRC risk per se, we
acknowledge that our power to demonstrate a relationship was
limited. Indeed, even the IVs for adult BMI we used explain B3%
of the total phenotypic variation in BMI (Locke et al, 2015).
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Figure 1. MR results of adiposity traits on CRC risk from seven GWAS studies and the meta-analysis. (A) Adult BMI; (B) adult WHR; (C) childhood
obesity (CO); and (D) birth weight (BW). Boxes denote OR point estimates, with their areas proportional to the inverse variance weight of the
estimate. Horizontal lines represent 95% CIs. The diamond represents the summary Ors, computed under a fixed-effects model, with 95% CI given
by the width of the diamond. The unbroken vertical line is at the null value (OR¼ 1.0).
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A possible explanation for a failure to demonstrate a significant
correlation between genetic BMI and CRC risk could be that the
distribution of body fat is a more important predictor of CRC risk in
men rather than total body adiposity. Support for this postulate is that
in men WHR has been reported to be superior in predicting CRC
than BMI in observational studies. In our MR-based analysis we
indeed found that WHR was associated with CRC in men but not in
women. Given that the genetic risk score for WHR is derived from
SNPs associated with WHR, which are adjusted for BMI, suggests that
fat distribution may be important for CRC risk for men, whereas
overall obesity is more important for CRC risk for women.
There is evidence that adiposity may have a more significant
effect on the development of colon rather than rectal cancer. Given
that the landscape of colonic and rectal cancers show differences
relating IVs to molecular features is likely to be informative in
terms of understanding disease aetiology (Yamauchi et al, 2012).
Unfortunately the data sets on which our study has been based did
not enable such analysis to be performed.
An important strength of our analysis is that by implementing
an MR-based analysis we have avoided the potential biases in
observational studies of factors such as recall bias and confound-
ing. The combined ratio estimates of the impact of adiposity on
CRC risk hold provided the marker is independent of factors that
may confound the relationship between adiposity and CRC. The
findings from our analysis are however reliant on a number of key
assumptions. First, that the IVs are solely associated with CRC
through its association with adiposity rather than pleiotropism,
which would be seen by a departure from linearity of the
relationship between SNPs and their effect size for adiposity and
CRC. We did not observe such a relationship between CRC and
adiposity risk SNPs. Second, the IV is independent of factors that
confound observational associations. To date there is currently no
evidence that the IVs we used are associated with factors that
might confound adiposity CRC associations in conventional
analyses. The generation of substantive IVs for highly complex
traits is a major limitation of the MR-based strategy to investigate
the aetiological basis of diseases like cancer.
Accepting these caveats our study findings can be viewed as
quantifying the causal effect of adiposity on CRC risk. Moreover,
they generally support previously published observational studies
and provide further evidence for adiposity being a major risk factor
for the development of CRC.
In the pooled analysis, genetically influenced BMI showed only
a statistically significant association with CRC in women. This
finding is discordant with observational studies which have
generally found a stronger correlation in men. It is possible that
some estimates from observational studies may have been biased
toward the null if heavier women under-report their weight.
Indeed it is noteworthy that this specific finding from the meta-
analysis is primarily driven by data from Thrift et al (2015), hence
independent replication is required.
The biological mechanism by which adiposity increases CRC
risk remains to be established and several mechanisms have been
variously suggested as explaining the correlation. These include
increased insulin and insulin-like growth factor signalling, chronic
inflammation and signalling via adipokines, such as leptin.
Furthermore, it is plausible that increased adiposity may alter the
intestinal microbiome, contributing to gastrointestinal carcinogen-
esis (Harriss et al, 2009; Kant and Hull, 2011; Aleman et al, 2014).
Irrespective of the exact functional basis of the association between
adiposity and CRC risk, demonstrating that it is causal makes
obesity an important target for primary prevention of CRC in the
population.
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